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A B S T R A C T
The treatment of chronic hepatitis C has made remarkable
progress over the past two decades. For interferon-
monotherapy, sustained virological response rates were
between 2 and 9% in genotype 1 and between 16 and 23%
in genotypes 2 and 3. By adjusting treatment duration up to
48 weeks for genotype 1 and combining regular interferon-
with ribavirin, sustained response rates could be improved
to 28 to 31% in genotype 1 and around 65% in genotypes
2 and 3. Attempts to further increase efficacy included the
addition of amantadine without conclusive evidence up till
now. With the recent introduction of long-acting pegylated
interferon- in combination with ribavirin, sustained viro-
logical response rates of 80% can be obtained in genotypes
2 and 3. However, sustained virological response rates for
patients with either genotype 1, nonresponse to prior
treatment, cirrhosis or a combination of these characteristics
are still less than 50%. In view of results with daily high-dose
interferon- induction in combination with prolongation
of treatment duration up to 18 months, such patients might
benefit from induction and prolonged PEG-IFN- treat-
ment and should be treated in an experimental setting. 
I N T R O D U C T I O N  
The Netherlands Journal of Medicine is an offspring of the
Folia Medica Neerlandica (1958). The very first publication
in this magazine was entitled: ‘Viruses as a cause of disease’,
a topic which has not lost its relevance.1
Hepatitis C virus (HCV) is such a cause and currently
leading to a global public health problem. Worldwide, 150 to
170 million people are estimated to be chronically infected
with HCV of whom an estimated five million are living in
Western Europe. Twenty percent of those chronically
infected will eventually develop cirrhosis of the liver and its
sequelae within 10 to 20 years in the absence of treatment.2
Antiviral therapy has now been used for nearly two
decades to slow down and prevent this progression. In
the past years, the response rate to antiviral therapy has
made remarkable progress.
Originally, the response to antiviral therapy in patients with
HCV was expressed in terms of biochemical response
(normalisation of serum alanine aminotransferase (ALT)
levels). However, since the introduction of sensitive PCR
assays for the detection of viral RNA, expression in terms of
virological response is preferred. Consequently, the success
of an antiviral treatment modality is expressed in terms of
sustained virological response, defined as a negative result of
a sensitive PCR assay for HCV-RNA after a 24-week treatment-
free follow-up period. A sustained virological response can
be regarded as a surrogate marker for cure of HCV, although
it does not completely exclude late virological relapse. 
The focus of this review is to summarise past treatments
of chronic hepatitis C, to describe the present standard of
care and to give recommendations how to improve therapy
in the future.
T R E A T M E N T  H I S T O R Y :  I N T E R F E R O N
A N D  R I B A V I R I N  
Interferon
In 1986, three years before the identification of the hepatitis
C virus by molecular cloning techniques, Hoofnagle et al.
introduced long-term, ‘low-dose’ interferon- (IFN-) for
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the treatment of chronic non-A and non-B hepatitis.3
Based on these preliminary data, large randomised placebo-
controlled trials were performed confirming the effectiveness
of IFN-.4,5 IFN- given as a single agent (monotherapy)
at a dose of 3 million units (MU) three times a week sub-
cutaneously for 24 weeks induced end of treatment
responses (normalisation of ALT levels) in about 50% of
patients. However, in about half of the responding
patients a relapse was seen within six months after dis-
continuation of treatment. Further experience indicated
that the sustained virological response was even lower;
only 6 to 18%. Patients with genotypes 2 and 3 had higher
sustained virological responses (16 to 23%) than patients
with the predominant genotype 1 (2 to 9%, table 1).6,7
In the years following the introduction of IFN-, strategies
to increase its antiviral activity included the optimisation
of dose, treatment duration and the combination with
other antiviral agents. One of the first improvements was
made by prolonging the treatment duration to 48 weeks.
Hereby, post-treatment relapse in HCV-RNA could be
reduced significantly, resulting in an increased sustained
virological response rate of 7 to 11% in genotype 1 and 29 to
33% in genotype non-1 (table 1).6,8 By therapy prolongation
beyond 12 months, the ALT relapse rate in IFN-
monotherapy could be reduced even further.9,10
Ribavirin
From all the efforts to increase efficacy, the combination
of IFN- with ribavirin has been the most fruitful.
Ribavirin, a nucleoside analogue in use for the treatment
of respiratory syncytial virus, lowers ALT levels in many
patients with chronic hepatitis C; it has however no sig-
nificant effect on serum HCV-RNA levels.11-13 When used
in combination with IFN-, it increases the end of treatment
response and reduces post-treatment relapse.7,14 Large
randomised placebo-controlled trials in the USA and
other countries have confirmed the enhanced efficacy of
combined interferon-ribavirin therapy. Among patients
with genotype 1, a sustained virological response was
found in 16 to 23% of those treated for six months and in
28 to 31% of patients treated for 12 months. Results in
genotype non-1 were around 65% for both six and 12 months
(table 1).6-8 These findings led to the recommendation that
patients infected with genotype 1 require a course of 48
weeks of IFN- plus ribavirin therapy whereas a 24-week
combination therapy was sufficient for patients with
genotypes 2 and 3.2
Amantadine
Amantadine has been used for many years to prevent
infection with influenza A virus. Most randomised con-
trolled trials were unable to demonstrate a significant
beneficial effect of amantadine-IFN- over IFN-
monotherapy, largely because of small sample sizes.15-19
The trials are comparable in design and when the data are
pooled – a total of 920 patients have been included – a
modest improvement can be demonstrated (table 2). Health-
related quality-of-life analysis showed an improvement in
fatigue and vigour scores in patients receiving combined
IFN- amantadine treatment compared with those treated
with IFN- alone.15,20 Two trials (one randomised) in IFN-
nonresponders demonstrated significant benefits from
the addition of amantadine to the combination of IFN-
and ribavirin.21,22 The mechanism with respect to this
improvement in sustained response remains unclear.
Currently a Dutch placebo-controlled multicentre trial on
‘triple’ therapy in naive patients is in progress in more
than 30 hospitals (CIRA study). This study will need a
large sample size to demonstrate beneficial effects of
amantadine.
High-dose induction and prolonged treatment
Increasing the IFN- dose or administrating IFN- daily
could be beneficial, because of the high viral replication
rate and the short half-life of IFN- (only hours).23 Indeed,
high-dose IFN- daily for several weeks, i.e. induction
therapy, has been used for years in Japan, resulting in
high (more than 80%) initial virological response rates24
High daily dose IFN- therapy with or without ribavirin
in Western Europe and the USA, however, had no lasting
beneficial effect on sustained virological response rates.25,26
In those early reports, a significant increase of virological
Vrolijk, et al. The treatment of hepatitis C: history, presence and future.
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Table 1
Effect of ribavirin and treatment duration
INTERFERON-B# INTERFERON-2B# AND RIBAVIRIN$
24 WEEKS 48 WEEKS 24 WEEKS 48 WEEKS
Genotype 1 2-96,7 7-116,8 16-236-8 28-316,8
Genotype non-1* 16-236,7 29-336,8 50-696-8 64-666,8
Sustained virological response rates in percentages in genotype 1 and genotype non-1 for interferon-2b (IFN) monotherapy and IFN plus ribavirin for 24 and
48 weeks. Between brackets the literature references from which the results are taken.
*Reflects data on genotypes 2 and 3, data on genotypes 4 to 6 are too limited for inclusion in the table. #Interferon-2b subcutaneously; dosed 3 million units
three times a week. $Ribavirin orally; dosed 1.0 to 1.2 g in two divided doses according to weight.
response rate (% HCV-RNA negative patients) was found
during the high daily dosing period as compared with
IFN- 3 MU three times a week. However, this effect did
not result in an increased sustained virological response.
This failure to maintain the initial response might be
explained by the premature lowering of the IFN- dose
within the first week27 or due to a short duration of treat-
ment which was stopped after 24 to 26 weeks (24). In a
later randomised controlled trial in 373 patients,28 two
experimental induction schedules were compared with a
regular schedule of 38 weeks IFN- 5 MU every other day.
In genotype 1 patients, the sustained virological response
was nearly twice as high (SVR: 42% versus 27%) when
treated with induction therapy (10 MU IFN- daily for
two weeks, followed by 10 MU every other day for 12
weeks, followed by 5 MU every other day for 24 weeks).
Sustained virological response rates in the non-1 genotypes
varied between 56 and 76% in the three treatment arms but
did not differ significantly. These data suggest beneficial
effects of high-dose induction and prolonged daily IFN-
dosing in genotype 1 patients in whom success is limited
when treated with standard therapy.
In an effort to analyse the above-mentioned treatment
strategies combining high-dose induction IFN- and
prolonged daily IFN- plus ribavirin we performed a
meta-analysis on individual treatment data of an exploratory
study performed in our centre.29 In total, 54 consecutive
chronic HCV patients selected for unfavourable baseline
characteristics associated with therapy resistance such as
genotype 1 infection, cirrhosis, previous nonresponse to
IFN- or combinations of these, were treated intensively
for 76 weeks. The first 24 patients were treated with a very
intensive schedule which resulted in an overall sustained
response rate of 67% (95% confidence interval 45 to
84%).30 In the following patients, attempts were made to
decrease morbidity and cost without losing efficacy.
However, by shortening the induction period adverse
effects decreased somewhat as did the effectiveness.27
Thus no clear advantage was found over the original
intensive treatment schedule.
The induction phase of 10 MU IFN- daily for two to four
weeks was followed by three to five MU IFN- injections
daily until week 52, and three MU daily or three times a
week until week 76. Throughout the study all patients
received 1000 to 1200 mg ribavirin. 
The overall sustained virological response rate was 57%
(95% CI 43 to 71%). Sustained virological response varied
between 75 and 83% for patients with one unfavourable
characteristic, between 25 and 60% for patients with two
unfavourable characteristics, but was only 17% for those
with three unfavourable factors. Ten patients had detectable
HCV RNA at week 12, in whom treatment was discontinued
(19%). Two patients experienced a virological breakthrough
(4%) and one patient was HCV RNA negative at 72 weeks
but relapsed in the 24 weeks of untreated follow-up (2%).
Four patients were not compliant: they stopped in the first
four weeks after discharge from hospital. In six patients
(11%), therapy was stopped because of adverse effects
(hepatic decompensation (n=2), depression (n=2), cardiac
symptoms (n=1) and Staphylococcus sepsis (n=1)). These data
indicate that patients with either genotype 1, cirrhosis or
prior nonresponse can have sustained virological response
rates approaching those in genotypes 2 and 3 when treated
with high-dosed and prolonged IFN- based therapy.
However, in patients with combinations of these unfavourable
criteria, sustained virological response rates were low.
T R E A T M E N T  T O D A Y :  P E G -
I N T E R F E R O N -  A N D  R I B A V I R I N  
PEG-interferon- monotherapy
The covalent attachment of polyethylene glycol (PEG) to
IFN- extends the half-life and duration of therapeutic
activity of IFN- in-vivo, allowing less frequent dosing. 
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Table 2
Effect of amantadine when added to interferon-
REFERENCE INTERFERON-2B INTERFERON-2B AND P*
AMANTADINE$
15 13/60 (22%) 6/59 (10%) 0.087
16 17/101 (17%) 29/99 (29%) 0.036
17 15/89 (17%) 21/90 (23%) 0.280
18 15/90 (17%) 22/90 (24%) 0.197
19 17/121 (14%) 25/121 (21%) 0.175
ALL 77/461 (17%) 103/459 (22%) 0.028
Number of patients out of whole group (and percentages between brackets) with sustained virological response for interferon-2b (IFN) monotherapy and IFN
plus amantadine for 48 weeks.
$Amantadine orally; dosed 200 mg in two divided doses. *Chi-square test.
Four randomised controlled trials have compared the
efficacy and safety of PEG-IFN- monotherapy with
standard IFN- monotherapy.31-34 One of these studies
was designed to investigate treatment efficacy and safety
in patients with bridging fibrosis or cirrhosis.32
Administration of PEG-IFN- once weekly has an
increased antiviral effect compared with IFN- 3 MU
three times a week in naive patients resulting in a reduced
breakthrough rate and an increased end of treatment and
sustained virological response rate. The optimal dose of
PEG-IFN- was found to be 180 g per week for PEG-
IFN-2a and 1.5 g/kg body weight for PEG-IFN-2b.
Sustained response rates in genotype 1 were between 12
and 31% for PEG-IFN- and between 2 and 6% for standard
IFN-. In genotypes 2 and 3 sustained virological
response rates were around 50 and 28%, respectively. 
PEG-interferon- and ribavirin
When PEG-IFN- is combined with ribavirin the sustained
response rate is further improved. Sustained virological
response rates in genotype non-1 were 78% for six and
77% for 12 months PEG-IFN-2a plus ribavirin therapy.
As with the treatment with regular IFN- plus ribavirin,
there is no benefit in prolonging treatment to 48 weeks
in patients with genotypes 2 and 3 (table 3). A reduced
ribavirin dose of 800 mg daily was found to be as effective
as 1000 to 1200 mg daily in patients with genotypes 2
and 3, but the standard dosage of 1000 to 1200 mg yielded
better sustained response rates in patients with genotype
1 in whom sustained virological response rates were 42 to
51% (table 4). These outcomes are improved over standard
IFN- ribavirin therapy although still about 50% of geno-
type 1 patients do not respond.35-37 During treatment, a 2
log or more decrease in viral load in the first 12 weeks is
predictive for sustained virological response. Patients who
fail to achieve a 2 log decrease in viral load have a limited
chance of achieving sustained virological response and
should stop therapy. 
One of the major differences between the two PEG-IFNs
is fixed dosing for PEG-IFN-2a and dosing according to
weight for PEG-IFN-2b. Trials comparing efficacy and
safety of PEG-IFN-2a to PEG-IFN-2b with or without
ribavirin have not (yet) been conducted. However, both
PEG-IFNs have been compared with standard IFN- and
the increased sustained response rates, safety profile and
side effects seem similar.
Consensus guidelines
The improvement in treatment results necessitated the
need for updating the available guidelines. Two consensus
guidelines, both funded from the public sector to assure
independence from the pharmaceutical industry, were
provided in 2002.38,39 According to the National Institutes
of Health (NIH) and French consensus guidelines all
Vrolijk, et al. The treatment of hepatitis C: history, presence and future.
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Table 3
Effect of pegylation of interferon-
INTERFERON- 2B# AND RIBAVIRIN¥ P-INTERFERON-2B/B AND RIBAVIRIN¥
48 WEEKS35,37 48 WEEKS35,37
Genotype 1 33-36% 42$-46%
Genotype non-1* 61-79% 76-82$ %
Sustained virological response rates in genotype 1 and genotype non-1 for interferon-2b and PEG-interferon- 2a or PEG-interferon-2b plus ribavirin for 48 weeks.
*Reflects data on genotypes 2 and 3, data on genotype 4 to 6 are too limited for inclusion in the table. #Interferon-2b dosed 3 million units three times a week.
PEG-interferon-2a dosed 180 g per week. PEG-interferon-2b dosed 1.5 g/kg body weight per week. ¥Ribavirin orally; dosed 1.0-1.2 g in two divided doses
according to weight. $Ribavirin orally: dosed 800 mg/ day in two divided doses.
Table 4
Effect of ribavirin dose and treatment duration36
PEG-INTERFERON-2A 180 G PER WEEK 
RIBAVIRIN 800 MG RIBAVIRIN 1-1.2 G
24 WEEKS 48 WEEKS 24 WEEKS 48 WEEKS
Genotype 1 29% 40% 41% 51%
Genotype 2-3 78% 73% 78% 77%
Sustained virological response rates in genotype 1 and genotypes 2 and 3 for PEG-interferon-2a ribavirin for 24 and 48 weeks.
patients with chronic hepatitis C and an increased risk of
developing cirrhosis are potential candidates for antiviral
therapy. Patients with genotypes 2 and 3 should be treated
for 24 weeks. The NIH guidelines state that sustained
virological response for patients with genotypes 2 or 3 are
similar to PEG-IFN- and ribavirin or standard IFN-
and ribavirin therapy. Thus standard IFN- and ribavirin
can still be used in treating patients with genotypes 2 or
3. Since low-dosed ribavirin was found to be as effective
as 1000 to 1200 mg daily, 24 weeks of treatment and an
800 mg dose of ribavirin is the new standard for patients
with genotypes 2 and 3. According to the consensus
statements, patients with genotype 1 should be treated
with PEG-IFN- in combination with 1 to 1.2 g ribavirin
for 48 weeks.
Currently, much attention is focused on patient and virus
characteristics to enable identification of patients who will
or will not benefit from treatment. Major pretreatment
factors influencing response rates to combination therapy
are HCV genotypes and the degree of fibrosis. Viraemic
level, age and gender are of less importance in pegylated
IFN- therapy.7,31,33,35,36,40
Since genotype 1 is the predominant genotype in many
parts of the world and the improved sustained response
rate with combined PEG-IFN- and ribavirin therapy is
only about 50%, more effective treatment for this large
group is desirable. 
Patients with cirrhosis form another group currently in need
of better treatment options. In view of the fact that morbidity
and mortality of chronic hepatitis C is predominantly in
this category of patients it is of note that most of the large
trials of the interferon-ribavirin combination as well as those
assessing PEG-IFN- with or without ribavirin contained
only a minority of patients with cirrhosis. Responses in
cirrhotic patients are generally less than in noncirrhotic
patients although treatment with PEG-IFN- has diminished
these differences. Heathcote et al. treated 271 patients
with bridging fibrosis or cirrhosis with IFN-2a versus
two schedules of PEG-IFN-2a. Sustained response rates
of 12% in genotype 1 and 51% in genotype non-1 infection
were found.32
T R E A T M E N T  T O M O R R O W :  F U R T H E R
T H E R A P E U T I C  O P T I O N S  F O R  
G E N O T Y P E  1  A N D  C I R R H O S I S
As described above, treatment with high-dose induction
IFN- and prolonged daily IFN- plus ribavirin was success-
ful in the majority of patients selected for treatment-
resistant characteristics. Given the increased effectiveness
of PEG-IFN-, a schedule of high-dose PEG-IFN-
combined with ribavirin for a prolonged period might
increase response rates. For PEG-IFN- induction, the
optimal PEG-IFN- dosage has to be determined by
measuring both the levels of IFN- and the antiviral
effects in vivo during therapy. Currently, a Dutch multi-
centre randomised trial (PIT study) comparing PEG-IFN-
induction and prolonged PEG-IFN- and ribavirin
combination treatment with standard therapy in previous
nonresponders is underway. Until now, randomised studies
comparing PEG-IFN- induction to standard PEG-IFN-
therapy have not yet been published.
In naive patients, interferon-based treatment strategies
can possibly be further tailored to each individual patient
according to early response dynamics. By measuring the
decline in viral load in each patient in the first weeks of
treatment, dose and treatment duration can possibly be
optimised. 
Completely different forms of medications, the so-called
proteinase-inhibitors, are being investigated for their
(additional) anti-HCV effect. These drugs can be taken
orally and appear highly effective. Phase II and III clinical
trials are currently underway; results are pending. Still,
it is unlikely that such new therapy will be available for
routine clinical use within the next three to five years.
C O N C L U S I O N S  A N D  
R E C O M M E N D A T I O N S  
In figure 1 our opinion on how to treat naive patients with
chronic hepatitis C is shown. 
Treatment is recommended for patients with an increased
risk of developing cirrhosis. Therefore patients with F0-1
(no or minor fibrosis) should only be treated when highly
motivated after complete information about side effects.
Genotype 2 and 3 patients without cirrhosis are optimally
treated for 24 weeks with (PEG)-IFN- in combination with
a low dose (800 mg/day) of ribavirin resulting in an 80%
sustained response rate. Patients with cirrhosis and geno-
types 2 and 3 have a limited chance of sustained response
when treated for 24 weeks and should therefore be treated
with PEG-IFN-2a/2b for 48 weeks in combination with
1000 to 1200 mg/day of ribavirin. Genotype 1 patients are
preferably treated with PEG-IFN-2a/2b in combination
with 1000 to 1200 mg/day of ribavirin for 48 weeks.
‘Difficult to treat patients’ with either genotype 1, nonresponse
to prior treatment, cirrhosis or a combination of these
characteristics who, despite notable advances, still have a
chance of less than 50% for sustained virological response
might benefit from induction and prolonged PEG-IFN-
treatment and should preferably be treated in an experimen-
tal setting. Further research is needed to optimise treatment
schedules and to investigate new antiviral drugs in clinical
practice; Dutch cooperative studies have the potential to
solve some of these outstanding issues.
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(PEG-)interferon-
ribavirin 800 mg
6 months
PEG-interferon-
ribavirin 1-1.2 g
12 months
HCV-RNA + (≥6 months)
Genotype 2/3 Genotype 1
ALT testing
Elevated Normal
Repeat 3 times
in 6 months
Liver biopsy
F0-1# F2-F3 F4$
ALT testing
Elevated Normal
Repeat 3 times
in 6 months
Liver biopsy
F2-F3 F4* F0-1#
Repeat in
3-5  years
Repeat in
3-5  years
Figure 1
Individualised approach to treatment of naive patients with chronic hepatitis C according to the authors’ interpretation
of consensus statements38,39
Treatment is recommended for patients with an increased risk of developing cirrhosis, characterised by detectable HCV RNA levels, elevated alanine
aminotransferase (ALT) values, a liver biopsy with portal or bridging fibrosis, and at least moderate inflammation and necrosis. 
# Patients with F0-1 (no or minor fibrosis) have a limited risk of developing cirrhosis and should only be treated when highly motivated after complete
information about side effects. Re-evaluation within three to five years is recommended. *Patients with genotype 1 and cirrhosis (F4) should in view of
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